Your session is about to expire
← Back to Search
Ripretinib vs Sunitinib for Gastrointestinal Stromal Tumor (INSIGHT Trial)
INSIGHT Trial Summary
This trial compares a new drug (ripretinib) to an existing one (sunitinib) to treat people with GIST who have progressed on a previous drug. Participants may switch to ripretinib if disease progresses.
INSIGHT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 & 3 trial • 78 Patients • NCT01164202INSIGHT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My GIST cancer has worsened despite being on imatinib.My cancer has a KIT mutation in exon 9, 13, or 14.I have cancer that has spread to my brain.I can take care of myself but might not be able to do heavy physical work.I can take pills and do not have issues with absorbing food or need IV feeding.I haven't taken drugs that affect CYP3A or had grapefruit in the last 14 days.I am 18 years old or older.My GIST has specific mutations in KIT exons 11 and either 17 or 18.I have HIV or hepatitis C but am not on excluded medications, or I don't have hepatitis B or C.I have not had major surgery in the last 4 weeks.My recent tests show my organs and bone marrow are working well.I am a woman who can have children and have a negative pregnancy test.I have serious heart issues, including recent heart attack or uncontrolled conditions.My side effects from previous treatments have mostly gone away.
- Group 1: Sunitinib
- Group 2: Ripretinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What hazards have been associated with Ripretinib for patients?
"We judge the safety of Ripretinib to be a 3, as there is evidence from multiple trials that demonstrate its effectiveness and security. This rating was generated due to this medication being in Phase 3 clinical trials."
How many people have signed up to participate in this experiment?
"Correct. Clinicaltrials.gov records show that this medical trial, initiated on August 1st 2023, is currently open to new applicants. The project seeks 54 participants across 3 locations for the study's duration."
Are enrollment opportunities presently available for this clinical trial?
"Affirmative. The clinicaltrials.gov website illustrates that this research project, originally posted on August 1st 2023, is presently recruiting participants. About 54 individuals must be recruited from 3 distinct medical centres across the country."
Share this study with friends
Copy Link
Messenger